Fidel Valea appointed to leadership roles in gynecologic oncology at Northwell Health

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Fidel A. Valea was appointed system chief of gynecologic oncology at Northwell Health and director of gynecologic oncology at the Northwell Health Cancer Institute. In these roles, he will see patients in New Hyde Park and Manhattan.

Valea is joining Northwell from the Virginia Tech Carilion School of Medicine, where he was chair of obstetrics and gynecology for five years. Prior to that, Valea held several leadership roles during his 12-year tenure at Duke University School of Medicine, including vice chair of education, residency program director in obstetrics and gynecology, fellowship director in gynecologic oncology, and tenured professor. 

In his role as system chief of gynecologic oncology at Northwell Health, Valea will direct gynecologic oncology programs across the health system. Key areas of responsibility include: advancing a patient-centered approach to care, overseeing performance improvement and quality assurance studies, enhancing operational efficiencies, developing educational and academic offerings for the fellowship program and other clinical staff, and expanding gynecologic oncology research efforts.

As director of gynecologic oncology at the Northwell Health Cancer Institute, Valea will direct the development of the gynecologic oncology program throughout the health system’s central region, working with Northwell’s Divi

sion of Gynecologic Oncology.

Valea recently completed his tenure as director of Gynecologic Oncology for the American Board of Obstetrics and Gynecology and served on its board. He is one of four editors of Comprehensive Gynecology. Valea’s research interests are in pre-invasive disease of the cervix, minimally invasive surgery, and evidence-based perioperative care. 

Table of Contents

YOU MAY BE INTERESTED IN

A year ago, when he was sworn in as director of the National Cancer Institute, Anthony G. Letai set a goal: Reassure cancer researchers that the institute will keep a steady course aimed at finding treatments for cancer.
Michael R. Caputo, a cancer survivor and a Republican political operative with a wide-ranging resume, was named to the President’s Cancer Panel, a board formed under the National Cancer Act to monitor the National Cancer Program and report to the president about “barriers to progress in reducing the burden of cancer.”
For over two decades, the ASCO Genitourinary Cancers Symposiumhas stood as the premier global event that has helped advance cancer science and transform care. The 2027 Symposium will continue this legacy from Feb. 11–13 in San Francisco by bringing together the largest international audience in GU oncology to help define tomorrow’s standards of care. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login